open access
Effectiveness and safety of sulodexide in the treatment of venous diseases
Affiliations- Instytut Gruźlicy i Chorób Płuc, Płocka 26, 01-138 Warszawa, Poland
open access
Abstract
This article presents a review of the literature assessing the effectiveness and safety of sulodexide in the prophylaxis
of deep vein thrombosis and treatment of chronic venous disease. It was demonstrated that sulodexide
is effective and safe in the prophylaxis of deep vein thrombosis and treatment of chronic venous insufficiency
with ulcers. Sulodexide is characterized by low frequency of bleeding complications.
Abstract
This article presents a review of the literature assessing the effectiveness and safety of sulodexide in the prophylaxis
of deep vein thrombosis and treatment of chronic venous disease. It was demonstrated that sulodexide
is effective and safe in the prophylaxis of deep vein thrombosis and treatment of chronic venous insufficiency
with ulcers. Sulodexide is characterized by low frequency of bleeding complications.
Keywords
sulodexide, venous thromboembolic disease, chronic venous disease
About this articleTitle
Effectiveness and safety of sulodexide in the treatment of venous diseases
Journal
Issue
Article type
Review paper
Pages
157-161
Published online
2019-09-30
Page views
816
Article views/downloads
1292
DOI
Bibliographic record
Acta Angiologica 2019;25(3):157-161.
Keywords
sulodexide
venous thromboembolic disease
chronic venous disease
Authors
Witold Zbyszek Tomkowski
Małgorzata Dybowska
References (27)- Zhang X, Sun D, Song JW, et al. Endothelial cell dysfunction and glycocalyx - A vicious circle. Matrix Biol. 2018; 71-72: 421–431.
- Rosenberg RD, Shworak NW, Liu J, et al. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest. 1997; 99(9): 2062–2070.
- Veraldi N, Guerrini M, Urso E, et al. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018; 156: 67–79.
- Tollefsen DM, He Li, Giri TK, et al. Vascular dermatan sulphate and heparin cofac-tor II. Prog Mol Biol Transl Sci. 2010; 93(1): 351–372.
- Marchi E, Barbanti M, Milani R, et al. Organ glycosaminoglycan distribution after intravenous and oral administration in rats. Semin Thromb Hemost. 1994; 20(3): 297–300.
- Mauro M, Ferraro G, Palmieri GC. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a dou-ble-blind, cross-over, placebo-controlled study. Curr Ther Res. 1992; 51: 342–50.
- Cerletti C, Rajtar G, Marchi E, et al. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost. 1994; 20(3): 245–253.
- Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019; 17(1): 31–38.
- Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004; 55(3): 243–249.
- Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006; 57(1): 53–64.
- Andreozzi GM, Bignamini AA, Davì G, et al. SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015; 132(20): 1891–1897.
- Tomkowski W, Kuca P, Urbanek T, et al. Venous thromboembolism — recommendations on the prevention, diagnostic approach and management. The 2017 Polish Consensus Statement. Acta Angiologica. 2017; 23(2): 35–71.
- Tomkowski W, Kuca P, Bignamini AA, et al. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials. Int Angiol. 2017; 36(5): 496–497.
- Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019; 17(1): 31–38.
- Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012; 12(2): 73–81.
- Cospite M, Ferrara F, Cospite V, et al. Sulodexide and the microcirculatory component in microphlebopathies. Curr Med Res Opin. 1992; 13(1): 56–60.
- Saviano M, Maleti O, Liguori L. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993; 13(2): 96–108.
- Coccheri S. Randomized, double-blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002; 87: 947–952.
- Scondotto G, Aloisi D, Ferrari P, et al. Treatment of venous leg ulcers with sulodexide. Angiology. 1999; 50(11): 883–889.
- Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie. 2003; 32(115): 120.
- Zhou YX, Feng X, Jing ZP. Efficacy and safety of sulodexide in the treatment of venous ulcers of leg. PharmCare Res. 2007; 7: 22–24.
- Nelson EA, Jones J. Venous leg ulcers. BMJ Clin Evid. 2008: 1902–1937.
- Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008; 27(1): 1–59.
- Luzzi R, Belcaro G, Dugall M, et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014; 20(6): 594–599.
- Elleuch N, Zidi H, Bellamine Z, et al. CVD study investigators. Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther. 2016; 33(9): 1536–1549.
- Borawski J, Dubowski M, Pawlak K, et al. Sulodexide induces hepatocyte growth factor release in humans. Eur J Pharmacol. 2007; 558(1-3): 167–171.
- Pletinck A, Van Landschoot M, Steppan S, et al. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol Dial Transplant. 2012; 27(2): 548–556.